Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.
Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.
Domain Therapeutics applies a multi-string corporate strategy to grow its business through:
PeptiMimesis secures €1.2m ($1.4m) from Cap Innov’Est
Ipsen and PeptiMimesis announce a research partnership in oncology
Domain will attend the AACR Annual Meeting 2016 on April 16-20, 2016 in New Orleans, Louisiana (USA)
New biotech startup developing next generation therapeutic peptides in immuno-oncology, oncology and immune diseases